Skip to main content

Table 2 Patient and tumor characteristics

From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer

Patient Sex Age Primary tumor site Previous operation Previous chemotherapy TNM (stage) Duration of follow-up after diagnosis (months) Site of metastasis Site of tomotherapy
1 F 53 Head No No T4N1M0(IVA) 2.9   Pancreas
2 M 61 Body Yes Gemcitabine #6, Cisplatin/Capecitabine T3N0M0 (II) 4.9   Pancreas
3 M 67 Tail No No T4N1M0(IVA) 1.5   Pancreas
4 F 76 Body No Gemcitabine #5 T4N1M0(IVA) 7.6   Pancreas
5 M 57 Body No Gemcitabine/Capecitabine T4N1M1(IVB) 1.2 Liver Pancreas
6 F 64 Body, tail No No T4N1M0(IVA) 0.2   Pancreas
7 M 67 Body No No T4N1M0(IVA) 1   Pancreas
8 F 71 Body No Gemcitabine/Cisplatin #3 T3N1M1(IVB) 8 Liver Pancreas
9 M 46 Body, tail No No T4N1M0(IVA) 0.7 Peritoneum Pancreas
10 F 80 Body, tail No No T3N1M0(III) 2.3   Pancreas
11 F 64 Tail No Gemcitabine/Cisplatin #1 T4N1M1(IVB) 1.3 Liver Pancreas, Liver
12 M 59 Head No No T3N1M1(IVB) 1.4 Liver Pancreas
13 M 68 Body, tail No No T4N1M1(IVB) 0.6 Liver Pancreas, Liver
14 F 54 Neck, body No Gemcitabine/5 - FU #2 T3N1M0(III) 5.5   Pancreas
15 M 57 Body Yes Gemcitabine, Cisplatin/5 FU #6 T4N1M1(IVB) 5.2 Liver Pancreas
16 M 83 Head No No T4N1M0(IVA) 0.2   Pancreas
17 M 54 Head No No T4N1M0(IVA) 0.2   Pancreas
18 M 64   Yes Gemcitabine/xeloda #9, Irinotecan #2 M1(IVB) 63.3 Lung Lung
19 M 58 Head No No T4N1M0(IVA) 2.4   Pancreas